StockNews.com Begins Coverage on DBV Technologies (NASDAQ … – MarketBeat
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Stock analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Rating) in a note issued to investors on Saturday. The firm set a “sell” rating on the stock.
Separately, The Goldman Sachs Group downgraded shares of DBV Technologies from a “neutral” rating to a “sell” rating in a research note on Friday, December 16th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, DBV Technologies currently has an average rating of “Hold” and a consensus target price of $5.63.
DBV Technologies Price Performance
Shares of NASDAQ DBVT opened at $1.44 on Friday. The company has a market cap of $270.79 million, a price-to-earnings ratio of -2.62 and a beta of 1.39. The stock’s 50-day moving average is $1.43 and its two-hundred day moving average is $1.97. DBV Technologies has a 1-year low of $1.08 and a 1-year high of $3.43.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC acquired a new position in DBV Technologies in the third quarter valued at $26,000. Advisory Services Network LLC acquired a new stake in shares of DBV Technologies in the 2nd quarter valued at about $26,000. Optiver Holding B.V. purchased a new position in DBV Technologies during the 3rd quarter worth approximately $36,000. BNP Paribas Arbitrage SA acquired a new position in DBV Technologies during the second quarter worth approximately $49,000. Finally, Two Sigma Investments LP lifted its stake in DBV Technologies by 80.9% in the third quarter. Two Sigma Investments LP now owns 35,920 shares of the company’s stock valued at $64,000 after buying an additional 16,066 shares during the last quarter. Institutional investors and hedge funds own 18.37% of the company’s stock.
About DBV Technologies
(Get Rating)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
Featured Articles
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DBV Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and DBV Technologies wasn’t on the list.
While DBV Technologies currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.